Cidara Therapeutics Inc

Cidara Therapeutics — Investor Presentation (January 2020)

51 slides from Cidara Therapeutics's investor presentation, Jan 13, 2020

  1. Slide 1: New Hope for Serious Infections

    New Hope for Serious Infections Corporate Presentation January 2020 © Cidara Therapeutics 2020

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Because such statements are subject to risks and observed attributes, represent an improvement These slides and the uncertainties, actual results may differ materially from those over existing therapies or will also be observed in expressed or implied by such forward-looki

  3. Slide 3: Cidara investment thesis

    SB 12 Cidara investment thesis Leading science on antifungal and antiviral prevention and treatment Rezafungin 1st antifungal in 13 years for 1st line treatment and prophylaxis Treatment – Phase 3 Catalyst: Phase 3 readout in 2020 supports NDA Prophylaxis – Phase 3 Transform prevention in high risk

  4. Slide 4: Cidara's pipeline targets fungal and viral infections

    Cidara’s pipeline targets fungal and viral infections Proposed IND- Indication Program Discov. in vitro in vivo enable Ph 1 Ph 2 Ph 3 REZAFUNGIN Candidemia & Treatment Invasive Candidiasis Blood & Marrow Prophylaxis Transplant Patients CLOUDBREAK Antiviral Fc Conjugates (AVCs) Prevention & Influenza

  5. Slide 5: Cidara's pipeline targets multiple unmet medical needs

    Cidara’s pipeline targets multiple unmet medical needs Rezafungin Cloudbreak 5

  6. Slide 6: Antifungals are historically big drugs globally

    Antifungals are historically big drugs globally Peak Annual Global Sales ($M) Diflucan 1000 Vfend 800 Noxafil 720 Cancidas 680 Ambisome 510 Mycamine 370 Source: IQVIA for all products in their respective peak sales year, other than Noxafil (2018 Merck Annual Report) and Diflucan (www.pharmaceuticalo

  7. Slide 7: Antifungal drug development has dwindled

    Antifungal drug development has dwindled Number of New Antifungals 5 5 1 1980 1990 2000 2010 2019 amphotericin POLYENES lipid forms (3) itraconazole posaconazole AZOLES fluconazole voriconazole micafungin ECHINOCANDINS caspofungin anidulafungin 7

  8. Slide 8: Cresemba faces several challenges

    SB 15 Cresemba faces several challenges Cresemba’s launch in the US has been a success, despite its limitations Percentage of Invasive Fungal Infections Other 12% Candidemia Aspergillosis and Candidiasis 73% 15% and Mucormycosis Rezafungin • Fourth in class azole • Approved for 15% of antifungal mar

  9. Slide 9: Antifungal launch outpaces antibacterials

    Antifungal launch outpaces antibacterials U.S. Sales Post Launch: Cresemba vs. Antibacterials 12030 ANTIFUNGAL AVYCAZ 8020 DALVANCE ZERBAXA ANTIBIOTICS AVERAGE 4010 ORBACTIV Annualized Sales ($M) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Launch Quarter Cresemba (isavuconazole) is a triazole launched in Q2 201

  10. Slide 10: Antifungals can have greater value than antibiotics

    Antifungals can have greater value than antibiotics Data Available at Signing Rights Deal ($ million) ANTIFUNGAL P2 P3 NDA Marketed Cidara / Mundipharma: Rezafungin Ex-US; ex-Japan 568 Basilea / Pfizer: Ex-US; ex-Japan 725 ANTIBIOTICS 0 200 400 600 P2 P3 NDA Marketed Melinta / Menarini: Delafloxacin

  11. Slide 11: Rezafungin: A novel echinocandin in Phase 3

    Rezafungin: A novel echinocandin in Phase 3 Structural modification is designed to yield improved chemical & biological properties • Designed for prolonged PK once weekly dosing in clinical studies • Designed for high exposures potential for improved efficacy • Observed absence of toxic degradation

  12. Slide 12: Echinocandins are constrained today

    Echinocandins are constrained today $4.2 Billion Treatment Prophylaxis $0.5 Polyenes Azoles $1.1 Echinocandins Outpatient Azoles/Bactrim Marketed $2.6 Azoles Echinocandins Inpatient Azoles/Bactrim Source: IQVIA, as of December 31, 2017 12

  13. Slide 13: An approval with non-inferiority enables Rezafungin

    An approval with non-inferiority enables Rezafungin Targets: outpatients, early hospital discharge and prophylaxis segments $4.2 Billion Treatment Prophylaxis $0.5 Polyenes Azoles $1.1 Echinocandins Outpatient Azoles/Bactrim Rezafungin Targets $2.6 Azoles Marketed Echinocandins Inpatient Azoles/Bact

  14. Slide 14: Rezafungin's global opportunity spans ID and hematology

    Rezafungin’s global opportunity spans ID and hematology The $4.2 billion global antifungal market Infectious Disease Hematology Mostly Treatment Mostly Prophylaxis Cancidas Noxafil (caspofungin) (posaconazole) ~$700M ~$700M REZAFUNGIN Source: Global sales for Cancidas – IQVIA; Noxafil – 2018 Merck A

  15. Slide 15: Rezafungin 2032 peak sales opportunity in US

    ~$745M Rezafungin 2032 peak sales opportunity in US, in ID and hematology Infectious Disease Hematology Mostly Treatment Mostly Prophylaxis Rezafungin in Treatment Rezafungin in Prevention ~$375M ~$370M Revenue projections based on estimates and assumptions, including estimated patient populations,

  16. Slide 16: Rezafungin overall phase development plan

    Rezafungin overall phase 3 development plan 1 Phase 3 Treatment Trial Phase 3 Prophylaxis Trial Treatment of candidemia & Prophylaxis against Aspergillus, Indication invasive candidiasis in patients Candida & PCP in allogeneic blood with limited treatment options and marrow transplant patients Phase

  17. Slide 17: STRIVE B Phase 2 data in candidemia & invasive candidiasis

    STRIVE B Phase 2 data in candidemia & invasive candidiasis Corroborates STRIVE A results and supports ReSTORE Phase 3 17

  18. Slide 18: STRIVE Program: Candidemia & Invasive Candidiasis

    P2 STRIVE Program: Candidemia & Invasive Candidiasis Not powered for inferential statistical analysis Mycological & EMA: Overall Response Mycological & N= 183 clinical (Mycological & clinical clinical response Mycological & response response) (IC only) clinical response Dose Optional dose FDA: All c

  19. Slide 19: Rezafungin: Superior on time to negative blood culture

    Rezafungin: Superior on time to negative blood culture Time to negative blood culture (mITT population) Rezafungin IV 400/200 100% Rezafungin IV 400/400 80% Caspofungin IV 60% Log-rank test: Combined RZF vs CSP 40% p=0.02 20% Probability of negative blood culture 0% 0 40 80 120 160 200 Hours since f

  20. Slide 20: 30-Day All Cause Mortality

    30-Day All Cause Mortality Similar to the ReSTORE trial primary endpoint recommended by FDA Death at Day 30 (%) mITT Population n/N= 1 Rezafungin 400/400 12/76 15.8% 2 Rezafungin 400/200 2/46 4.4% 3 All Rezafungin 14/122 11.5% 4 Caspofungin 8/61 13.1% Source: Table 14.2.5.2c 1. 400 mg dose once week

  21. Slide 21: 30-Day All Cause Mortality – Post Hoc Analysis

    30-Day All Cause Mortality – Post Hoc Analysis* STRIVE Program: Rezafungin vs. Caspofungin FAVORS REZAFUNGIN FAVORS CASPOFUNGIN ReSTORE -8.8% Phase 3 trial endpoint -24.7% Rezafungin 400/200 +0.41% requires upper limit of 95% confidence interval confidence interval be below 20% threshold -1.6% for F

  22. Slide 22: Day 14 Clinical Response

    Day 14 Clinical Response Similar to the ReSTORE trial primary endpoint recommended by EMA Clinical Cure (%) at Day 14 mITT Population n/N= 1 Rezafungin 400/400 53/76 69.7% 2 Rezafungin 400/200 37/46 80.4% 3 All Rezafungin 90/122 73.8% 4 Caspofungin 43/61 70.5% Source: Table 14.2.4.1c 1. 400 mg dose

  23. Slide 23: Day 14 Clinical Response – Post Hoc Analysis

    Day 14 Clinical Response – Post Hoc Analysis* STRIVE Program: Rezafungin vs. Caspofungin FAVORS REZAFUNGIN FAVORS CASPOFUNGIN ReSTORE 9.9% Phase 3 trial endpoint 26.6% Rezafungin 400/200 -6.9% requires upper limit of 95% confidence interval confidence interval be below 20% threshold 3.3% for EMA 17.

  24. Slide 24: STRIVE safety data: no concerning adverse events or trends

    STRIVE safety data: no concerning adverse events or trends RZF RZF RZF CAS 400/400 400/200 Pooled N=81 N=53 N=134 N=68 STRIVE n (%) n (%) Subjects with TEAEs 71 (87.7) 49 (92.5) 120 (89.6) 55 (80.9) Related 7 (8.6) 6 (11.3) 13 (9.7) 9 (13.2) Subject with SAEs 35 (43.2) 28 (52.8) 63 (47.0) 29 (42.6)

  25. Slide 25: ReSTORE trial design mirrors STRIVE

    ReSTORE trial design mirrors STRIVE Phase 2 Dose Optional dose Week 1 2 3 4 5 6 7 8 9 N= 183 Day 1 8 15 22 28 45 59 All cause mortality Mycological & clinical response: 1° ENDPOINT Overall response: All cause mortality: 1° ENDPOINT EMA 1° ENDPOINT FDA Phase 3 Week 1 2 3 4 5 6 7 8 9 N= 184 Objective:

  26. Slide 26: Our partner for Rezafungin ex-US/Japan

    Our partner for Rezafungin ex-US/Japan 120 60 Over €2 50% MARKETS YEARS BILLION Active in Over 60 years of asset- European sales Over 50% revenue derived from new more than 30 led innovation exceeding €1 billion products launched in in Europe Over €2B ex-US the last five years in Europe 26

  27. Slide 27: Rezafungin collaboration recognizes commercial potential

    Rezafungin collaboration recognizes commercial potential ANTIFUNGAL ANTIBACTERIAL Product: Vabomere, Product: rezafungin Product: Product: delafloxacin Product: omadacycline Orbactiv & Minocin Rights: ex-US/Japan Rights: Europe & Asia- Rights: ex-US/Japan Pacific (ex-Japan) Rights: ex-US/Japan Right

  28. Slide 28: Rezafungin overall phase development plan

    Rezafungin overall phase 3 development plan 1 Phase 3 Treatment Trial Phase 3 Prophylaxis Trial Treatment of candidemia & Prophylaxis against Aspergillus, Indication invasive candidiasis in patients Candida & PCP in allogeneic blood with limited treatment options and marrow transplant patients Phase

  29. Slide 29: The current standard of care is inadequate

    The current standard of care is inadequate BMT patients discontinue prophylaxis due to adverse events and low tolerability High Posaconazole1 34% 1 discontinuation rate Fluconazole 38% 2 Bactrim 35% 90-day mortality in patients with invasive fungal infection3 High Blood and marrow transplant 63% mor

  30. Slide 30: Rezafungin: potential simplified single drug paradigm

    Rezafungin: potential simplified single drug paradigm Antifungal prophylaxis in allogeneic blood and marrow transplant setting Fluconazole SOC for Current Fluconazole Posaconazole or Voriconazole Candida and Antifungal Aspergillus Prophylaxis or… Posaconazole or Voriconazole Regimens SOC for Bactrim

  31. Slide 31: Cidara's pipeline targets multiple unmet medical needs

    Cidara’s pipeline targets multiple unmet medical needs Rezafungin Cloudbreak 31

  32. Slide 32: Flu vaccines have well known limitations

    SB 11 Flu vaccines have well known limitations… Viral coverage Patient Manufacturing Strain-specific, Less effective in elderly & Challenging in a pandemic: variable coverage immune compromised long, complex production 10%-60% effective ~2-week lag time to Difficult to scale, low yields (2004-2018)1

  33. Slide 33: Flu places a substantial burden on the US population

    … which place a substantial burden on the US population 49% 40% or less 9M to 45M immunization rate vaccine effectiveness people who get the flu 31.4M 140K – 810K 12K – 80K outpatient visits hospitalizations deaths The top range of these burden estimates are from the 2017-2018 flu season Sources: CD

  34. Slide 34: On average, the flu costs the US economy ~$33B/yr

    On average, the flu costs the US economy ~ $33B/yr $7B $10.4B $16.3B In sick days / lost direct medical lost earnings for productivity for expenses patients / caregivers employers (17M missed workdays) Sources: CDC; Challenger, Gray, & Christmas, Inc.; https://www.healthline.com/health/influenza/fac

  35. Slide 35: What would an ideal product look like?

    SB 12 What would an “ideal” product look like? Broad spectrum, universal coverage Superior resistance profile Protection for High-Risk Populations Expanded efficacy window Long duration of action Rapid onset of activity Flexible administration 35

  36. Slide 36: Cloudbreak platform – multimodal mechanism of action

    SB 10 Cloudbreak platform – multimodal mechanism of action intrinsic antimicrobial activity & immune engagement Immune Pathogen Component TARGETING MOIETY (TM) Fc MOIETY Binds conserved surface target Engages innate or Direct antimicrobial activity adaptive immune system 36

  37. Slide 37: Cloudbreak AVCs combine small molecules and monoclonal antibodies

    SB 9 Cloudbreak AVCs combine the power of small molecules and monoclonal antibodies • High potency small molecule TMs • Broad spectrum (influenza A&B) Intrinsic antiviral • Extended half-life activity • Combining multiple MOAs VIRUS Conserved, essential target AVCs (Antiviral Conjugates) are not tra

  38. Slide 38: CD377 is highly potent in vivo – Influenza A & B

    CD377 is highly potent in vivo – Influenza A & B Single SC dose, lethal influenza models - BALB/c mice A/California/07/2009 A/Hong Kong/1/68 H1N1pdm H3N2 100 100 80 CD377 – 0.3 mg/kg 80 CD377 – 0.3 mg/kg 60 Vehicle 60 Vehicle 40 40 % Survival % Survival 20 20 0 0 0 2 4 6 8 10 12 14 0 2 4 6 8 10 12 1

  39. Slide 39: CD377 retains potency versus Tamiflu resistant viruses

    CD377 retains potency versus Tamiflu resistant viruses Single SC dose, lethal influenza models - BALB/c mice H1N1 A/Perth/261/2009 H275Y CD377 - 0.3 mg/kg 100 80 60 Tamiflu 20 mg/kg Vehicle % Survival 40 BID x 5 20 0 0 2 4 6 8 10 12 14 Days Post Infection 5 mice per cohort CD377 dosed 2 hours post i

  40. Slide 40: CD377 demonstrates lower resistance potential than baloxavir and oseltamivir

    SB 2+3 CD377 demonstrates lower resistance potential than baloxavir and oseltamivir vs. A/CA/07/2009 H1N1pdm Serial Passage (MOI 0.01) 107 Vehicle Baloxavir (4 nM) 6 10 Oseltamivir (100 nM) 105 Viral titer, (PFU/mL) 104 CD377 (4 nM) 103 2 4 6 8 10 Passage Number 40

  41. Slide 41: CD377 demonstrates durable protection in immune compromised hosts

    CD377 demonstrates durable protection in severely immune compromised hosts Lethal influenza model (H1N1: A/Puerto Rico/8/34 in mice) Efficacy in BALB/c SCID mice 100 CD377 0.3 mg/kg (single) 80 Baloxavir 3 mg/kg (BID x 1) 60 % Survival 40 Vehicle CD377 0.1 mgkg (single) 20 0 0 2 4 6 8 10 12 14 16 18

  42. Slide 42: CD377 extends the treatment window

    SB 14 CD377 extends the treatment window Lethal influenza model (H1N1: TX/36/91 in mice) Dosing 72 hours post infection Dose 100 CD377: 1 mg/kg Doses CD377 80 Oseltamivir: 20 mg/kg 60 % Survival 40 Oseltamivir 20 Vehicle 0 0 2 4 6 8 10 12 14 Day post infection 0 24 48 72 96 HOURS INFECTION 5 mice/co

  43. Slide 43: Potential for long-term single dose protection

    Potential for long-term single dose protection Single 1 mg/kg subcutaneous dose protects mice from pandemic H1N1 for a month CD377: 1 mg/kg 100 80 60 % Survival 40 Vehicle 20 Dose Infect -28 -24 -20 -16 -12 -8 -4 0 4 8 12 Day post infection Single 1 mg/kg doses were fully protective vs H1N1 (above),

  44. Slide 44: Efficacious by multiple dosing routes

    Efficacious by multiple dosing routes Lethal influenza model (A/California/07/2009 H1N1pdm) CD377 dosed once 2 hours after viral challenge Efficacy of CD377 dosed by different routes PK of CD377 dosed by different routes (BALB/c (BALB/c mouse) 0.1 mg/kg mouse) 5 mg/kg IV 100 100 IM SC 80 10 IV 60 IM

  45. Slide 45: Broad safety margin in primates (CD377)

    Broad safety margin in primates (CD377) Results of 14-day toxicity testing Therapeutic Margin 30000 NO FINDINGS FOR: Area under the curve Clinical observations (AUC) for maximum dose tested (hr*µg/mL) Hematology 20000 Clinical Chemistry Coagulation 54x Urinalysis 10000 Immunophenotyping Cytokines AU

  46. Slide 46: Cloudbreak platform: potential applications beyond influenza

    Cloudbreak platform: potential applications beyond influenza INFLUENZA RSV HIV OTHER VIRUSES 46

  47. Slide 47: Financial overview

    Financial overview Summary Consolidated Balance Sheet Information As of September 30, 2019 Cash and cash equivalents $73.8M Common stock issued1 33,873,084 Common equivalent shares issued2 39,525,394 New common equivalent shares expected 11,952,191 from Rights Offering (to close Feb 13) Pacific West

  48. Slide 48: Rights Offering Summary

    Rights Offering Summary $30M Rights Offering Priced at $2.51 (15% discount to 30 day VWAP) Fully backstopped by BVF Partners and Stonepine Capital Every Cidara common and preferred stockholder and 2018 warrant holder on January 21 is an “eligible investor” Each eligible investor can buy 0.22971 shar

  49. Slide 49: Rights Offering Attributes

    Rights Offering Attributes Every eligible investor can buy their pro rata part of the offering • Each share bought/settled by January 21 at 5:00 pm ET receives a “right” • If every eligible investor fully participates, there’s no backstop Demonstrates investors’ support • $30M is guaranteed through

  50. Slide 50: Cidara is much more than a typical ID company

    SB 12 Cidara is much more than a typical ID company Strategic Focus Transformative approaches to infectious disease Rezafungin Treatment Enable discharge & outpatient treatment on standard of care Rezafungin Prophylaxis Transform the care of BMT patients Cloudbreak AVC Radically different approach t

  51. Slide 51: New Hope for Serious Infections

    New Hope for Serious Infections Corporate Presentation January 2020 © Cidara Therapeutics 2020

Cidara Therapeutics — Investor Presentation (January 2020) on 6ix